Contact Us
Drug Search Results
More Filters [+]

Sertraline

Alternative Names: sertraline, zoloft, SERTRALINA, sertralin, lustral
Latest Update: 2024-12-18
Latest Update Note: News Article

Product Description

Sertraline is a medication used to manage and treat the major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder. It is in the SSRI class of medications. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31613469/)

Mechanisms of Action: SSR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Generalized anxiety disorder | Obsessive-Compulsive Disorder | Panic Disorder | Depressive Disorder | Depressive Disorder, Major | Premenstrual Dysphoric Disorder | Stress Disorders, Post-Traumatic

Known Adverse Events: Tremor | Stress Disorders, Post-Traumatic | Hyperhidrosis | Diarrhea | Dyspepsia

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sertraline

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Stress Disorders, Post-Traumatic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT04174170

P3

Completed

Stress Disorders, Post-Traumatic

2023-07-25

NCT04124614

P3

Completed

Stress Disorders, Post-Traumatic

2023-07-19

Recent News Events

Date

Type

Title

12/18/2024

News Article

 JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults

09/04/2024

News Article

 Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

08/15/2024

News Article

 Lykos Therapeutics Announces Reorganization to Address FDA's Recent Decision on Midomafetamine Capsules for PTSD

08/09/2024

News Article

 Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions